Summary Box: Amgen CEO sees higher sales in 2012

Mon, 01/09/2012 - 11:45am
The Associated Press

RISING TIDE: Robert Bradway, on deck as Amgen's next CEO, predicts newer products and expanding operations into more countries to bring higher revenue down the road.

MOMENTUM: Positive developments include last year's purchase of a cancer vaccine developer and moves to protect long-term sales of top seller Enbrel, for psoriasis and rheumatoid arthritis, and anemia treatment Epogen.

MANAGEMENT MOVES: Along with Bradway, Amgen has appointed new heads of commercial operations and research and development. It also plans more share buybacks.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.